Cantor Fitzgerald L. P. Acquires New Position in Avalo Therapeutics, Inc. $AVTX

Cantor Fitzgerald L. P. acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 85,247 shares of the company’s stock, valued at approximately $1,083,000. Cantor Fitzgerald L. P. owned 0.47% of Avalo Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AVTX. Bank of America Corp DE grew its holdings in shares of Avalo Therapeutics by 49.0% during the 3rd quarter. Bank of America Corp DE now owns 605,842 shares of the company’s stock valued at $7,700,000 after acquiring an additional 199,271 shares in the last quarter. Boothbay Fund Management LLC grew its stake in Avalo Therapeutics by 1,916.6% in the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after purchasing an additional 216,976 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in Avalo Therapeutics in the third quarter valued at about $2,264,000. Ameriprise Financial Inc. acquired a new position in Avalo Therapeutics in the 3rd quarter worth about $2,714,000. Finally, Caligan Partners LP purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $10,592,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Trading Down 5.4%

Shares of Avalo Therapeutics stock opened at $15.80 on Monday. The firm has a fifty day simple moving average of $15.89 and a 200-day simple moving average of $15.56. The stock has a market capitalization of $292.46 million, a price-to-earnings ratio of -2.95 and a beta of 0.84. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $20.72.

Wall Street Analyst Weigh In

AVTX has been the subject of several research reports. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, January 15th. Guggenheim started coverage on shares of Avalo Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.